OBJECTIVE: To investigate the expression level of Galectin-9 (Gal-9) in the serum of cervical cancer patients and analyze the clinic significance of it. METHODS: Collected sera from 29 patients with cervical cancer, 45 patients with cervical inter-epithelial lesion (CIN) and 26 normal females. Determination of Gal-9 was performed by ELISA, and in the group of patients with cervical cancer, these results were compared with the serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP). Then selecting four patients from the invasive cervical cancer group performed Gal-9 retrospective immuno-staining analysis. RESULTS: Gal-9 concentration was 27.15 ng/L in the group of patients with cervical cancer that was significantly higher compared with the patients with CIN (21.20 ng/L) and the normal females (17.43 ng/L), and the Gal-9 concentration was significantly correlated with both VEGF and CRP in cervical cancer group. Two of these patients, who had a higher Gal-9 serum level, shown more intense staining and the other two patients, with lower serum level of Gal-9, had moderate immunostaining, suggesting that at least part of serum Gal-9 might be produced by cervical cancer tissue. CONCLUSIONS: Gal-9 might play a role in the progression and invasion of cervical cancer and warrants further study.
OBJECTIVE: To investigate the expression level of Galectin-9 (Gal-9) in the serum of cervical cancerpatients and analyze the clinic significance of it. METHODS: Collected sera from 29 patients with cervical cancer, 45 patients with cervical inter-epithelial lesion (CIN) and 26 normal females. Determination of Gal-9 was performed by ELISA, and in the group of patients with cervical cancer, these results were compared with the serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP). Then selecting four patients from the invasive cervical cancer group performed Gal-9 retrospective immuno-staining analysis. RESULTS:Gal-9 concentration was 27.15 ng/L in the group of patients with cervical cancer that was significantly higher compared with the patients with CIN (21.20 ng/L) and the normal females (17.43 ng/L), and the Gal-9 concentration was significantly correlated with both VEGF and CRP in cervical cancer group. Two of these patients, who had a higher Gal-9 serum level, shown more intense staining and the other two patients, with lower serum level of Gal-9, had moderate immunostaining, suggesting that at least part of serum Gal-9 might be produced by cervical cancer tissue. CONCLUSIONS:Gal-9 might play a role in the progression and invasion of cervical cancer and warrants further study.
Authors: Annika Stiasny; Christoph P Freier; Christina Kuhn; Sandra Schulze; Doris Mayr; Christoph Alexiou; Christina Janko; Irmi Wiest; Christian Dannecker; Udo Jeschke; Bernd P Kost Journal: Oncol Lett Date: 2017-08-14 Impact factor: 2.967